Ouédraogo Jean Claude Romaric Pingdwindé, Ilboudo Sylvain, Bado Prosper, Compaoré Tegwindé Rebeca, Tougma Alix, Nitiéma Mathieu, Zouré Abdou Azaque, Belemnaba Lazare, Ouédraogo Sylvin, Savadogo Léon Gueswendé Blaise
Drug Development Laboratory, African Centre of Excellence for Training, Research and Expertise in Drug Sciences, (LADME/CEA-CFOREM), Joseph Ki-Zerbo University, Ouagadougou, Burkina Faso.
Phytomedicines and Medicines Research and Development Laboratory (LR-D/PM), Research Institute for Health Sciences (IRSS)/ CNRST, Ouagadougou, Burkina Faso.
Infect Dis Poverty. 2024 Jun 12;13(1):45. doi: 10.1186/s40249-024-01212-5.
In 2023, Burkina Faso experienced the largest dengue epidemic ever in Africa. This study aimed to estimate the prevalence of symptomatic, subclinical, and asymptomatic dengue and determine the associated factors among adult contacts of dengue in the Central Region, Burkina Faso.
This cross-sectional study included contacts of dengue probable cases through cluster sampling in 2022-2023. These suspected cases that tested positive were identified from the five health facilities (Pissy CMA, Saaba CM, Kossodo CMA, Samandin CM, and Marcoussis CSPS) that reported the highest number of cases in 2021 per district. All participants underwent dengue and malaria rapid diagnostic tests (RDT). Samples positive for non-structural 1 protein antigen (AgNS1) and/or immunoglobulin M (IgM) were tested for serotype detection by reverse transcription polymerase chain reaction (RT-PCR). Binary logistic regression was done to identify the determinants of asymptomatic, subclinical, and symptomatic dengue among contacts of probable dengue cases.
A total of 484 contacts were included, mostly in 2023 (75.2%). Most participants were females (58.6%), residing (24.3%) and passing their daytime (23.1%) in Saaba. The overall prevalence of dengue was estimated at 15.1% [95% confidence interval (CI): 12.0-18.6%], representing cases not seeking care in hospitals. Asymptomatic cases represented 2.9% (95% CI: 1.6-4.8%). Subclinical and symptomatic cases accounted for 6.0% (95% CI: 4.1-8.5%) and 6.2% (95% CI: 4.2-8.7%), respectively. Of the 58 samples tested by RT-PCR, 10 were confirmed for serotype 3 in 2023. Malaria cases were estimated at 5.6% (95% CI: 3.7-8.0%). After adjustment, participants claiming that a virus transmits dengue were likelier to have asymptomatic dengue [adjusted odds ratio (aOR) = 7.1, 95% CI: 2.4-21.0]. From the multivariable analysis, subclinical dengue was statistically associated with being included in the study in 2023 (aOR = 30.2, 95% CI: 2.0-455.5) and spending the daytime at Arrondissement 4 (aOR = 11.5, 95% CI: 1.0-131.0). After adjustment, symptomatic dengue was associated with living less than 50 m away from cultivated land (aOR = 2.8, 95% CI: 1.1-6.9) and living less than 50 m from a stretch of water (aOR = 0.1, 95% CI: 0.0-0.6).
The overall burden of dengue among populations not seeking care in hospitals was quite high, with few asymptomatic cases. Efforts to manage dengue cases should also target non-hospital cases and raise population awareness. The 2023 epidemic could be due to dengue virus (DENV)-3.
2023年,布基纳法索经历了非洲有史以来最大规模的登革热疫情。本研究旨在估计有症状、亚临床和无症状登革热的患病率,并确定布基纳法索中部地区登革热成年接触者中的相关因素。
这项横断面研究通过2022 - 2023年的整群抽样纳入登革热疑似病例的接触者。这些检测呈阳性的疑似病例是从2021年每个区报告病例数最多的五家医疗机构(皮西CMA、萨阿巴CM、科索多CMA、萨曼丁CM和马尔库西CSPS)中识别出来的。所有参与者都接受了登革热和疟疾快速诊断检测(RDT)。对非结构1蛋白抗原(AgNS1)和/或免疫球蛋白M(IgM)呈阳性的样本通过逆转录聚合酶链反应(RT-PCR)进行血清型检测。采用二元逻辑回归来确定登革热疑似病例接触者中无症状、亚临床和有症状登革热的决定因素。
共纳入484名接触者,大部分在2023年(75.2%)。大多数参与者为女性(58.6%),居住在萨阿巴(24.3%)且白天在萨阿巴度过(23.1%)。登革热的总体患病率估计为15.1%[95%置信区间(CI):12.0 - 18.6%],这代表未在医院就诊的病例。无症状病例占2.9%(95% CI:1.6 - 4.8%)。亚临床和有症状病例分别占6.0%(95% CI:4.1 - 8.5%)和6.2%(95% CI:4.2 - 8.7%)。在通过RT-PCR检测的58个样本中,2023年有10个被确认为血清型3。疟疾病例估计为5.6%(95% CI:3.7 - 8.0%)。调整后,声称病毒传播登革热的参与者更有可能患无症状登革热[调整优势比(aOR)= 7.1,95% CI:2.4 - 21.0]。从多变量分析来看,亚临床登革热在统计学上与2023年纳入研究(aOR = 30.2,95% CI:2.0 - 455.5)以及在第4区度过白天(aOR = 11.5,95% CI:1.0 - 131.0)相关。调整后,有症状登革热与居住在距离耕地不到50米处(aOR = 2.8,95% CI:1.1 - 6.9)以及居住在距离一片水域不到50米处(aOR = 0.1,95% CI:0.0 - 0.6)相关。
未在医院就诊人群中的登革热总体负担相当高,无症状病例较少。登革热病例管理工作还应针对非医院病例并提高人群意识。2023年的疫情可能是由登革热病毒(DENV)-3引起的。